{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:59Z","timestamp":1760145179746,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Technology of the People\u2019s Republic of China","award":["2020YFC0842100","2020YFC0860600","2020BCB041"],"award-info":[{"award-number":["2020YFC0842100","2020YFC0860600","2020BCB041"]}]},{"name":"Key Research and Development Program of Hubei Province","award":["2020YFC0842100","2020YFC0860600","2020BCB041"],"award-info":[{"award-number":["2020YFC0842100","2020YFC0860600","2020BCB041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The emergence of SARS-CoV-2 variants of concern (VOCs) with increased transmissibility and partial resistance to neutralization by antibodies has been observed globally. There is an urgent need for an effective vaccine to combat these variants. Our study demonstrated that the B.1.351 variant inactivated vaccine candidate (B.1.351V) generated strong binding and neutralizing antibody responses in BALB\/c mice against the B.1.351 virus and other SARS-CoV-2 variants after two doses within 28 days. Immunized K18-hACE2 mice also exhibited elevated levels of live virus-neutralizing antibodies against various SARS-CoV-2 viruses. Following infection with these viruses, K18-hACE2 mice displayed a stable body weight, a high survival rate, minimal virus copies in lung tissue, and no lung damage compared to the control group. These findings indicate that B.1.351V offered protection against infection with multiple SARS-CoV-2 variants in mice, providing insights for the development of a vaccine targeting SARS-CoV-2 VOCs for human use.<\/jats:p>","DOI":"10.3390\/vaccines12070742","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:35:57Z","timestamp":1720006557000},"page":"742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-5657","authenticated-orcid":false,"given":"Jie","family":"Yang","sequence":"first","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifen","family":"Fan","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Yang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjie","family":"Lin","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"You","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deqin","family":"Pang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changfu","family":"Guo","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Shi","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Wuhan Institute for Neuroscience and Neuroengineering, South-Central University for Nationalities, Wuhan 430074, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinguo","family":"Li","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Duan","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Shen","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-9506","authenticated-orcid":false,"given":"Shengli","family":"Meng","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-3215","authenticated-orcid":false,"given":"Zejun","family":"Wang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China"},{"name":"National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China"},{"name":"National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China"},{"name":"Hubei Province Vaccine Technology Innovation Center, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","article-title":"Broad sarbecovirus neutralization by a human monoclonal antibody","volume":"597","author":"Tortorici","year":"2021","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s12250-021-00376-w","article-title":"Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates","volume":"36","author":"Yao","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/22221751.2020.1852059","article-title":"Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models","volume":"9","author":"Wang","year":"2020","journal-title":"Emerg. Microbes. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jmv.27541","article-title":"OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear","volume":"94","author":"Thakur","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Phillips, N., Cyranoski, D., and Mallapaty, S. (2020). A leading coronavirus vaccine trial is on hold: Scientists react. Nature.","DOI":"10.1038\/d41586-020-02594-w"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/d41586-021-00268-9","article-title":"Novavax offers first evidence that COVID vaccines protect people against variants","volume":"590","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: Milestones, lessons, and prospects","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22848","DOI":"10.1038\/s41598-021-01930-y","article-title":"Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals","volume":"11","author":"Maeda","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning Immunity after the BNT162b2 Vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","article-title":"Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB\/XBB.1.5-Related Sublineages Among Immunocompetent Adults\u2014Increasing Community Access to Testing Program, United States, December 2022\u2013January 2023","volume":"72","author":"Ciesla","year":"2023","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A Bivalent Omicron-Containing Booster Vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiac158","article-title":"Omicron BA.1, BA.2 and COVID-19 Booster Vaccination","volume":"226","author":"Assawakosri","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microbes. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2020.05.002","article-title":"The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells","volume":"547","author":"Rothan","year":"2020","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e2381","DOI":"10.1002\/rmv.2381","article-title":"Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.jve.2021.100054","article-title":"Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India)","volume":"7","author":"Sanches","year":"2021","journal-title":"J. Virus Erad."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41392-021-00623-2","article-title":"SARS-CoV-2 mutations, vaccines, and immunity: Implication of variants of concern","volume":"6","author":"Noh","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41392-021-00796-w","article-title":"The way of SARS-CoV-2 vaccine development: Success and challenges","volume":"6","author":"Dong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2200592119","DOI":"10.1073\/pnas.2200592119","article-title":"Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles","volume":"119","author":"Syed","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ruhl, L., K\u00fchne, J.F., Beushausen, K., Keil, J., Christoph, S., Sauer, J., and Falk, C.S. (2023). Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1120010"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chi, W.Y., Li, Y.D., Huang, H.C., Chan, T.E.H., Chow, S.Y., Su, J.H., Ferrall, L., Hung, C.F., and Wu, T.C. (2022). COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci., 29.","DOI":"10.1186\/s12929-022-00853-8"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:49Z","timestamp":1760108989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["vaccines12070742"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12070742","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}